These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17761588)

  • 1. Regulation of follow-on biologics.
    Frank RG
    N Engl J Med; 2007 Aug; 357(9):841-3. PubMed ID: 17761588
    [No Abstract]   [Full Text] [Related]  

  • 2. Market exclusivity for biologics.
    Wheadon DE
    N Engl J Med; 2010 Feb; 362(7):661; author reply 661-2. PubMed ID: 20164494
    [No Abstract]   [Full Text] [Related]  

  • 3. The new follow-on-biologics law: a section by section analysis of the patent litigation provisions in the Biologics Price Competition and Innovation Act of 2009.
    Dougherty MP
    Food Drug Law J; 2010; 65(2):231-45, i. PubMed ID: 24475541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No longer "if," but "when": the coming abbreviated approval pathway for follow-on biologics.
    Kelly JJ; David M
    Food Drug Law J; 2009; 64(1):115-48. PubMed ID: 19998743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. US biotech prepares to fight generic biologics.
    Reid B
    Nat Biotechnol; 2002 Apr; 20(4):322. PubMed ID: 11923820
    [No Abstract]   [Full Text] [Related]  

  • 6. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 7. The market for follow-on biologics: how will it evolve?
    Grabowski H; Cockburn I; Long G
    Health Aff (Millwood); 2006; 25(5):1291-301. PubMed ID: 16966725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution?
    Silbermann JM
    J Contemp Health Law Policy; 1996; 12(2):607-36. PubMed ID: 8666736
    [No Abstract]   [Full Text] [Related]  

  • 9. A new era in drug regulation?
    Dresser R
    Hastings Cent Rep; 2005; 35(3):10-1. PubMed ID: 16092391
    [No Abstract]   [Full Text] [Related]  

  • 10. US market: 2008 priorities.
    Novelli T
    Med Device Technol; 2008; 19(3):58. PubMed ID: 18557412
    [No Abstract]   [Full Text] [Related]  

  • 11. Regulating off-label drug use--rethinking the role of the FDA.
    Stafford RS
    N Engl J Med; 2008 Apr; 358(14):1427-9. PubMed ID: 18385495
    [No Abstract]   [Full Text] [Related]  

  • 12. Rules for evaluating biosimilars put applicants through hoops.
    Morrow T
    Manag Care; 2012 Mar; 21(3):56-7. PubMed ID: 22471166
    [No Abstract]   [Full Text] [Related]  

  • 13. Scientific and legal viability of follow-on protein drugs.
    Dudzinski DM; Kesselheim AS
    N Engl J Med; 2008 Feb; 358(8):843-9. PubMed ID: 18287608
    [No Abstract]   [Full Text] [Related]  

  • 14. Tobacco, public health, and the FDA.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2009 Jul; 361(4):402-3. PubMed ID: 19546344
    [No Abstract]   [Full Text] [Related]  

  • 15. [Biosimilars or follow-on biologics in dermatology].
    Puig L
    Actas Dermosifiliogr; 2010; 101(1):4-6. PubMed ID: 20109387
    [No Abstract]   [Full Text] [Related]  

  • 16. Is it a cosmetic, a drug, or both? (Or is it soap?).
    Center for Safety and Applied Nutrition/Office of Cosmetics and Colors US Food and Drug Administration
    Plast Surg Nurs; 2008; 28(4):195-7. PubMed ID: 19092587
    [No Abstract]   [Full Text] [Related]  

  • 17. Trying times at the FDA--the challenge of ensuring the safety of imported pharmaceuticals.
    Schweitzer SO
    N Engl J Med; 2008 Apr; 358(17):1773-7. PubMed ID: 18434648
    [No Abstract]   [Full Text] [Related]  

  • 18. The danger of imperfect regulation: OxyContin use in the United States and Canada.
    Lexchin J; Kohler JC
    Int J Risk Saf Med; 2011; 23(4):233-40. PubMed ID: 22156088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attorney General's intrusion into clinical practice.
    Noah L
    N Engl J Med; 2002 Jun; 346(24):1918-9; author reply 1918-9. PubMed ID: 12066817
    [No Abstract]   [Full Text] [Related]  

  • 20. Playing "kick the FDA"--risk-free to players but hazardous to public health.
    Wood AJ
    N Engl J Med; 2008 Apr; 358(17):1774-5. PubMed ID: 18434649
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.